Galidesivir
Antiviral drug candidate
Galidesivir | |
---|---|
![]() | |
INN | |
Drug class | |
Routes of administration | |
Pregnancy category | |
Bioavailability | |
Metabolism | |
Elimination half-life | |
Excretion | |
Legal status | |
CAS Number | |
PubChem | |
DrugBank | |
ChemSpider | |
KEGG |
Galidesivir (also known as BCX4430) is an antiviral drug candidate that is being developed by BioCryst Pharmaceuticals. It is a broad-spectrum antiviral that has shown activity against a variety of RNA viruses, including the Ebola virus, Marburg virus, Zika virus, and coronaviruses.
Mechanism of Action[edit | edit source]
Galidesivir is a nucleoside analog that interferes with the replication of viral RNA. It is incorporated into the growing RNA strand during viral replication, leading to premature termination of the RNA chain. This mechanism is similar to that of other nucleoside analogs, which mimic the natural building blocks of RNA and disrupt the viral replication process.
Development and Research[edit | edit source]
Galidesivir was initially developed as a treatment for Ebola virus disease and Marburg virus disease. Preclinical studies demonstrated its efficacy in animal models, leading to further investigation for use in humans. The drug has also been studied for its potential to treat other viral infections, including those caused by Zika virus and coronaviruses.
In response to the COVID-19 pandemic, Galidesivir was evaluated for its effectiveness against SARS-CoV-2, the virus responsible for COVID-19. Clinical trials were conducted to assess its safety and efficacy in treating COVID-19 patients.
Clinical Trials[edit | edit source]
Galidesivir has undergone several phases of clinical trials to evaluate its safety and efficacy. Early trials focused on its use against Ebola virus and Marburg virus, while later studies expanded to include other viral infections. The results of these trials have been mixed, with some showing promise in reducing viral load and improving patient outcomes.
Potential Applications[edit | edit source]
Due to its broad-spectrum antiviral activity, Galidesivir has potential applications in treating a wide range of viral infections. Its ability to target multiple viruses makes it a valuable candidate for addressing emerging viral threats and pandemics.
Challenges and Future Directions[edit | edit source]
While Galidesivir has shown promise in preclinical and early clinical studies, challenges remain in its development. These include optimizing its pharmacokinetic properties, ensuring its safety in humans, and demonstrating its efficacy in large-scale clinical trials. Ongoing research aims to address these challenges and explore the full potential of Galidesivir as an antiviral therapy.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD